Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study

Overview of attention for article published in Blood, November 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (77th percentile)
Good Attention Score compared to outputs of the same age and source (67th percentile)

Mentioned by

news: 1 news outlet

So far, Altmetric has seen 3 news stories from 1 outlets.

Emerging Agents Signal Promising Opportunities to Expand Treatment Options for CLL

OncLive, 15 Dec 2022

Anthony Mato, MD, MSCE Sequencing agents for the treatment of chronic lymphocytic leukemia (CLL) is fast becoming an area of…

Addressing Intolerance and Resistance to BTK Inhibition Is Next Frontier in CLL Drug Development

OncLive, 09 Nov 2022

The development of agents to address intolerance and acquired resistance to BTK inhibitors addresses 2 of the major unmet needs…

BRUIN CLL-313 Trial To Evaluate Pirtobrutinib in Untreated CLL/SLL

OncLive, 12 Jun 2022

The phase 3 BRUIN CLL-313 trial is currently recruiting patients with treatment naïve chronic lymphocytic leukemia or small…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.